To search for product information for reagents, ancillaries and bulks please visit your local Catalog for Healthcare Professionals in eLabDoc, an eService within dialog.roche.com.
Predictive IHC assay
VENTANA PD-L1 (SP263) Assay identifies patients who are most likely to respond to TECENTRIQ therapy, so that you can make informed, efficient treatment decisions that can lead to better clinical outcomes and improved quality of life. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.
VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying NSCLC patients eligible for treatment with TECENTRIQ®.
VENTANA PD-L1 (SP263) Assay expands immunotherapy options for NSCLC patients through equipping pathologists by:
VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemistry assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the programmed death ligand-1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue specimens by light microscopy. The VENTANA PD-L1 (SP263) Assay is used with the OptiView DAB IHC Detection Kit for staining on the BenchMark ULTRA instrument.
PD-L1 protein expression in ≥ 1% TC in NSCLC tissue is indicated as an aid in identifying NSCLC patients for treatment with Tecentriq (atezolizumab). *
Table 1. Therapy and associated indication.View Full Table
Table 1. Therapy and associated indication.
|Indication for use||Therapy||PD-L1 Expression|
*Please refer to the VENTANA PD-L1 (SP263) Assay method sheet for the full intended use statement and approved therapeutic labeling.